Cafepharma Today

May 15 2025 - FDA approves Amneal's self-administered migraine treatment
FDA approves Amneal's self-administered migraine treatment
VC firm reveals plan for 30K-square-foot biotech incubator space in New Jersey
Philips taps Nvidia to build AI model for MRI
FDA delays decision on Biohaven's rare disease drug filing, plans adcomm
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Raptor Pharmaceuticals announces positive data on RP103 extension study
The Fly on the Wall
Monday, November 5, 2012 - 11:02am
tags:
RP103, Raptor Pharmaceuticals, nephropathic cystinosis
How Do You Solve a Problem Like Vascepa?
Motley Fool
Monday, November 5, 2012 - 11:01am
tags:
Vascepa, Amarin
China Diabetes Triples Creating $3.2 Billion Drug Market
Bloomberg
Monday, November 5, 2012 - 10:59am
tags:
diabetes, China
Otsuka's Investigational Compound for Autosomal Dominant Polycystic Kidney Disease (ADPKD), Tolvaptan, Meets Primary Endpoint in a Phase III Clinical Trial
Business Wire
Sunday, November 4, 2012 - 10:54am
tags:
Otsuka, Tolvaptan, autosomal dominant polycystic kidney disease, kidney disease
New Clinical Trial Data Show Substantial Improvement with Eculizumab (Soliris®) in Patients with STEC-HUS
Business Wire
Sunday, November 4, 2012 - 10:52am
tags:
Soliris, hemolytic uremic syndrome, Alexion
Why Investors Should Be Concerned About Dendreon
Motley Fool
Sunday, November 4, 2012 - 10:49am
tags:
Dendreon
Pfizer - Company Is Still Cleaning Up After Wyeth Mega-Merger
Seeking Alpha
Sunday, November 4, 2012 - 10:45am
tags:
Pfizer, M&A
Is MannKind Back on Track?
Motley Fool
Sunday, November 4, 2012 - 10:45am
tags:
MannKind
Theravance: Still A Buy On Weakness
Seeking Alpha
Sunday, November 4, 2012 - 10:44am
tags:
Theravance
New drug holds promise as therapy for rare and deadly cholesterol disorder
Equities.com
Sunday, November 4, 2012 - 10:43am
tags:
lomitapide, hypercholesterolemia, Aegerion
China Biotech In Review: Charles River Labs Buys China's Vital River
Seeking Alpha
Sunday, November 4, 2012 - 10:30am
tags:
Charles Grassley, Vital River, Guangxi, Guangxi Wuzhou Pharma, Fosun Pharmaceutical, China MediTech, Sihuan Pharmaceutical, Xiamen Innovax Biotech, Innovent Biologics
Arena Looks To Be The Clear Winner In The Weight Loss Space
Seeking Alpha
Sunday, November 4, 2012 - 10:27am
tags:
Arena Pharmaceuticals, Vivus, Qsymia, weight loss, obesity, Belviq
Medicis Pharmaceutical Larger Than S&P 500 Component Pitney Bowes
Forbes
Saturday, November 3, 2012 - 11:45am
tags:
Medicis
Shionogi enters into license agreement with Janssen for Alzheimer's treatment
Equities.com
Saturday, November 3, 2012 - 11:44am
tags:
Shionogi, Janssen Pharmaceuticals, Alzheimer's disease
Merck Settles Vioxx Lawsuit
Daily Finance
Saturday, November 3, 2012 - 11:43am
tags:
Merck, Vioxx, lawsuits
3 Pharmaceutical Stocks to Sell Now
InvestorPlace
Saturday, November 3, 2012 - 11:41am
tags:
Warner Chilcott, Sagent Pharmaceuticals, Pemix Therapeutic Holdings
Ensemble inks $186M deal with Boehringer Ingelheim
Mass High Tech, MA
Saturday, November 3, 2012 - 11:40am
tags:
Ensemble Therapeutics, Boehringer
Valeant profit plummets as acquisition costs pile up
Financial Post, CA
Saturday, November 3, 2012 - 11:39am
tags:
Valeant Pharmaceuticals
Why Investors Are Excited About Dendreon's Earnings
Motley Fool
Saturday, November 3, 2012 - 11:36am
tags:
Dendreon, earnings
Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess of $100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact the Firm
Yahoo/PR Newswire
Saturday, November 3, 2012 - 11:36am
tags:
Keryx, lawsuits

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline
The GLP-1 Saga Continues, And How
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.